Effects of SRX246, a Vasopressin 1a Receptor (V1a) Antagonist, on an Experimental Model of Phasic and Sustained Threat in Humans

Category Primary study
JournalBiological Psychiatry
Year 2020
This article has no abstract
Epistemonikos ID: 72a6e5283ce3249c47f4fb05c9a4e6af2128d8ce
First added on: Feb 11, 2025